NASDAQ
24.12.24
18:42 Uhr
12,320 US-Dollar
+0,050
+0,41 %
+0,41 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Chefanwältin von Cullinan Therapeutics verkauft Aktien im Wert von 39.729 US-Dollar | 1 | Investing.com Deutsch | ||
| Fr | Wissenschaftliche Leiterin von Cullinan Therapeutics verkauft Aktien im Wert von 53.547 US-Dollar | 1 | Investing.com Deutsch | ||
| Fr | Medizinischer Leiter von Cullinan Therapeutics verkauft Aktien im Wert von 52.851 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.11. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | 121 | GlobeNewswire (Europe) | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| 07.11. | Wissenschaftliche Leiterin von Cullinan Therapeutics verkauft Aktien im Wert von 125.120 US-Dollar | - | Investing.com Deutsch | ||
| 07.11. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 | 1 | GlobeNewswire (USA) | ||
| 24.10. | UBS sees upside in Cullinan Oncology stock as key trials approach | 5 | Investing.com | ||
| 24.10. | UBS sieht Potenzial in Cullinan Oncology-Aktie vor wichtigen Studien | 2 | Investing.com Deutsch | ||
| 17.10. | Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval | 1 | Investing.com | ||
| 17.10. | Cullinan Oncology: H.C. Wainwright erhöht Kursziel um 5% und bleibt nach FDA-Zulassung optimistisch | 1 | Investing.com Deutsch | ||
| 16.10. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus | 60 | GlobeNewswire (Europe) | CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.... ► Artikel lesen | |
| 18.09. | Cullinan Oncology behält "Kaufen"-Bewertung von H.C. Wainwright mit stabilem Kursziel | 1 | Investing.com Deutsch | ||
| 18.09. | Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target | 2 | Investing.com | ||
| 17.09. | Cullinan Therapeutics startet Phase-1-Studie für Lupus-Behandlung | 1 | Investing.com Deutsch | ||
| 17.09. | Cullinan Therapeutics commences Phase 1 trial for lupus treatment | 1 | Investing.com | ||
| 17.09. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus | 144 | GlobeNewswire (Europe) | Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in multiple... ► Artikel lesen |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | +0,41 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,740 | -0,24 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,340 | -1,15 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,881 | +0,60 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,390 | -0,11 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,980 | -0,33 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,430 | +0,68 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,300 | -1,81 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,785 | +0,26 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,940 | -0,32 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,030 | -0,96 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,41 % bei einem Aktienkurs von 12,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.
